Jeff Jaeckel
Jeff has notable experience representing public and private corporations in connection with their most significant and complicated antitrust litigation in federal and state courts. He regularly represents clients in all antitrust aspects of complicated transactional matters, including strategy and structuring of transactions to avoid antitrust risk and achieve strategic business objectives, and U.S. and multinational merger notification and review. Jeff also represents domestic and international companies in connection with government investigations of conduct, including civil investigations relating to monopolization or criminal investigations of alleged price-fixing. Jeff also assists clients in the protection of their intellectual property and counsels clients on the antitrust ramifications of commercial agreements to capitalize on the value of intellectual property.
Jeff represents clients across a range of industries, including pharmaceuticals and medical devices, semiconductors, software, Internet services, transportation, consumer products, telecommunications, and media and entertainment.
In addition to his active practice, Jeff is Morrison Foerster’s Vice Chair. Jeff formerly served as co-chair of Morrison Foerster’s Global Antitrust Law Practice Group and as a member of the firm’s Board of Directors, and co-chair of the firm’s eDiscovery Task Force.
Jeff serves as an associate editor of the Antitrust Magazine of the American Bar Association Antitrust Section. He graduated with honors and was a member of Omicron Delta Epsilon, the international honor society in Economics. He was a writing staff member for the Wisconsin Environmental Law Journal, and was elected to Order of the Coif.
Experience
SoftBank / Clearwire Corporation
Represented SoftBank in connection with the acquisition by Sprint Nextel of the approximately 50% of the equity of Clearwire Corporation that Sprint does not already own for a purchase price of approximately $4 billion, resulting in a total Clearwire enterprise value of approximately $14 billion.
Fujisawa Pharmaceutical Co. / Yamanouchi Pharmaceutical Co.
Represented Fujisawa Pharmaceutical Co. and Yamanouchi Pharmaceutical Co. before the Federal Trade Commission in connection with their $7 billion merger to form Astellas Pharma Inc., Japan’s second largest pharmaceutical company.
SoftBank / Sprint Nextel
Represented SoftBank in its $21.6 billion acquisition of a 78% interest in U.S. wireless operator Sprint Nextel. The transaction was the largest announced U.S. M&A transaction of 2012, the largest outbound investment ever from Asia, and the largest U.S. M&A transaction in Japan’s history.
Elpida Memory
Represented Elpida Memory, a Tokyo-based DRAM manufacturer, in its $2.5 billion sale to Micron Technologies, making Micron the world’s second-largest DRAM manufacturer.
International Air Cargo Cartel Investigation
Represented major international transportation company in connection with an investigation in the U.S., Japan, and South Korea related to alleged price-fixing in the air cargo industry.
International Freight Forwarding Cartel Investigation & Litigation
Represents major international transportation company in the U.S., EU, Brazil, and Asia in connection with an investigation of alleged price-fixing in the freight forwarding industry and related class action civil litigation.
AirTran Baggage Fee Antitrust Investigation & Litigation
Represents AirTran Airways in a Department of Justice investigation into allegations that our client conspired with Delta Air Lines to set airline baggage fees, and in parallel class action civil litigation.
U.S. Department of Justice Investigation of Major International Transportation Company
Secured summary judgment on behalf of international transportation company in antitrust litigation alleging that our client conspired with FedEx to boycott certain consultants in the shipping industry .
Semiconductor Industry Cartel Investigation
Represents Asian semiconductor manufacturer in connection with an investigation in the U.S., EU, and Canada related to allegations of price-fixing.
Astellas Pharma Inc.
ACON Laboratories
Represented ACON Laboratories in antitrust and intellectual property against Inverness Medical Innovations, and before the FTC in connection with settlement of litigation and Inverness’s $200 million acquisition of ACON’s rapid diagnostics
Epitomics
Represented Epitomics before the FTC in connection with its $155 million acquisition by Abcam to create new leader in rabbit monoclonal antibody technology.
InSound Medical
Represented InSound Medical, creator of novel in-ear hearing aid products, before the FTC in connection with its $75 million acquisition by Sonova.
Genentech / Tanox
Represented Tanox Inc. before the Federal Trade Commission in its $919 million acquisition by Genentech.
Southwest / AirTran
Represented AirTran Holdings, Inc. before the U.S. Department of Justice in connection with Southwest Airlines Co.’s $1.4 billion acquisition of AirTran.
ON Semiconductor/Sanyo Semiconductor
Represented ON Semiconductor Corp. in connection with its $600 million acquisition of Sanyo Semiconductor Co. Ltd.
Clearwire / Sprint Nextel
Represented Clearwire Corporation, an innovative wireless communications company developing next-generation wireless broadband technology called WiMAX, before the U.S. Department of Justice in a deal with Sprint Nextel Corporation, Intel Corporation, Google, Inc., Comcast Corporation, Time Warner Cable Inc., and Bright House Networks to create a national WiMAX joint venture valued at approximately $14.5 billion.
Astellas Pharma Inc. $537 million Acquisition
Represented Astellas Pharma Inc., Japan’s second-largest drug maker, in its acquisition of Agensys Inc., a leading U.S.-based biotechnology unit developing several novel cancer treatments.
Astellas Pharma Merger
Represented Fujisawa Pharmaceutical Co. and Yamanouchi Pharmaceutical Co. before the Federal Trade Commission in connection with its $7 billion merger to form Astellas Pharma Inc., Japan’s second-largest pharmaceutical company.
Celltech Ltd.
Represented Celltech Ltd. in intellectual property and antitrust litigation against MedImmune Inc.
Merger of Sankyo and Daiichi Pharmaceutical
Represented Sankyo Co. and Daiichi Pharmaceutical Co. before the Federal Trade Commission in relation to its multibillion-dollar merger to form Daiichi Sankyo.
Sale of Alltel to Verizon Wireless
Represented Alltel Corporation before the Department of Justice in its $28 billion acquisition by Texas Pacific Group and Goldman Sachs, and in its $28.5 billion acquisition by Verizon Wireless to create the largest wireless operator in the U.S.
Rankings
Recognized as a Leading Lawyer
Who's Who Legal: Competition 2024
Ranked in Antitrust: Merger Control
Legal 500 US 2017-2024
Ranked in Antitrust: Civil Litigation/Class Actions: Defense
Ranked in Antitrust: Cartel
Legal 500 US 2015-2018 and 2020-2021
Ranked for Antitrust, District of Columbia